Lion Point Capital, LP 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Lion Point Capital, LP disclosed 27 US equity positions worth $17.6m in its Q3 2025 13F filing. The largest position was MLYS at 8.4% of the reported book, followed by MIST and FENC. Against the Q2 2025 filing, it opened 9 new positions, added to 3 and reduced 8 among the top 27 holdings.
What did Lion Point Capital, LP own in Q3 2025? Top 27 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 8.4% | $1.5m | 39,000 | -51% | reduced |
| 2 | MIST MILESTONE PHARMACEUTICALS IN | 7.5% | $1.3m | 658,553 | 20% | added | |
| 3 | FENC FENNEC PHARMACEUTICALS INC | 6.5% | $1.2m | 123,000 | -37% | reduced | |
| 4 | JSPR JASPER THERAPEUTICS INC | 5.4% | $948.6k | 398,558 | 172% | added | |
| 5 | AVADEL PHARMACEUTICALS PLC | 5.2% | $911.6k | 59,700 | -40% | reduced | |
| 6 | KINIKSA PHARMACEUTICALS INTL | 5.2% | $908.6k | 23,400 | -49% | reduced | |
| 7 | INSM INSMED INC | Healthcare | 5.1% | $900.1k | 6,250 | -41% | reduced |
| 8 | ARDX ARDELYX INC | Healthcare | 5.1% | $896.8k | 162,750 | -51% | reduced |
| 9 | BENITEC BIOPHARMA INC | 4.9% | $869.9k | 62,000 | 0% | held | |
| 10 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 4.8% | $846.2k | 55,000 | 0% | held |
| 11 | RPRX ROYALTY PHARMA PLC | Healthcare | 4.3% | $755.0k | 21,400 | – | new |
| 12 | IRON DISC MEDICINE INC | Healthcare | 4.0% | $700.4k | 10,600 | 0% | held |
| 13 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 3.9% | $690.8k | 13,300 | -49% | reduced |
| 14 | GERN GERON CORP | Healthcare | 3.9% | $685.0k | 500,000 | 0% | held |
| 15 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 3.8% | $665.4k | 35,300 | -24% | reduced |
| 16 | RGNX REGENXBIO INC | Healthcare | 3.2% | $557.3k | 57,750 | 0% | held |
| 17 | SERES THERAPEUTICS INC | 3.0% | $522.1k | 27,138 | 59% | added | |
| 18 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 2.7% | $484.0k | 67,500 | – | new |
| 19 | KURA KURA ONCOLOGY INC | Healthcare | 2.3% | $407.1k | 46,000 | – | new |
| 20 | BHVN BIOHAVEN LTD | Healthcare | 1.9% | $340.7k | 22,700 | 0% | held |
| 21 | CMPS COMPASS PATHWAYS PLC | Healthcare | 1.9% | $332.3k | 58,000 | – | new |
| 22 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.7% | $302.1k | 5,700 | – | new |
| 23 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.7% | $296.1k | 42,000 | – | new | |
| 24 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 1.6% | $280.4k | 86,000 | – | new |
| 25 | MRSN MERSANA THERAPEUTICS INC | 1.1% | $199.9k | 25,760 | – | new | |
| 26 | HUMA HUMACYTE INC | 0.8% | $145.3k | 83,500 | 0% | held | |
| 27 | SPRB SPRUCE BIOSCIENCES INC | 0.1% | $8.9k | 1,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.